Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Johnson & Johnson reports robust quarter, but full-year earnings slip
(Sharecast News) - Johnson & Johnson reported robust growth in sales and earnings in its fourth quarter numbers on Tuesday, with sales rising 7.3% year-on-year to $21.4bn. Adjusted earnings per share for the quarter came in at $2.29, surpassing expectations by a narrow margin.
For the full year, Johnson & Johnson reported sales of $85.2bn, representing a 6.5% growth rate.
However, full-year earnings per share decreased to $5.20, mainly due to a one-time charge incurred in the first quarter.
Adjusted full-year earnings per share reached $9.92, making for an 11.1% increase.
"Johnson & Johnson's full year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients," said chairman and chief executive officer Joaquin Duato.
"We have entered 2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation."
Looking ahead, Johnson & Johnson forecast sales between $87.8bn and $88.6bn for 2024, with adjusted earnings per share in the range of $10.55 to $10.75.
The company said its medical devices segment generated $7.67bn in sales, driven by factors including the acquisition of Abiomed and increased demand for electrophysiological products, wound closure products, orthopaedic trauma devices, and contact lenses.
It added that a rebound in demand for nonurgent surgeries among older adults also contributed to the segment's growth.
In the pharmaceutical division, J&J reported $13.72bn in sales, with notable contributions from drugs such as Darzalex, Erleada, and Stelara.
However, the company faced challenges with declining sales of Zytiga and Imbruvica.
J&J noted that it had also entered into agreements to delay the launch of biosimilar competitors for Stelara until 2025.
The company said it was set to begin price negotiations with the federal Medicare program for Stelara and Xarelto, following the Inflation Reduction Act passed by Joe Biden in 2022.
It warned that the negotiations were expected to impact drug prices in 2026.
Despite its positive financial performance, Johnson & Johnson was still grappling with lawsuits related to its talc-based products.
The company was set to assume talc-related liabilities in the US and Canada, CNBC reported, following the separation of its consumer health unit Kenvue.
A federal bankruptcy judge rejected the company's attempt to resolve the lawsuits in bankruptcy, with appeals pending.
At 0821 EST (1321 GMT), shares in Johnson & Johnson were down -0.09% in premarket trading at $162.33.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.